![]() The New York-based Synergy Pharmaceuticals went bust in 2016, while Synergy Pharmaceuticals Australia stayed in business. ![]() Even more confusing is that there are two companies sharing the name. Its name is a bit confusing considering that its catalog features only natural vitamins. Synergy Pharmaceuticals is one such company currently facing pushback from the FDA. Given these historical patterns, it comes as no surprise that the FDA is opposed to natural medicine, especially when alternative treatments threaten to cut into pharmaceutical companies’ market share. Despite extensive research that shows sugar is the leading cause of heart disease and diabetes, the FDA has gone so far as to endorse it, fearing the ramifications that a warning label could have on agriculture producers and the greater food production industry. (Many of those approvals, for prescription medicines like Isotretinoin, Pemoline, and Propoxyphene, were eventually recalled after causing patient deaths or irreversible damage.) And this dynamic hasn’t been limited to medical treatments. Over several decades, the Food and Drug Administration (FDA) has gone to great lengths to maintain its longstanding relationship with major pharmaceutical companies, namely by approving numerous medications. The results concluded the 5CC as being an effective treatment option for the herpes simplex virus.How the Cure for Herpes Became Mired in Controversy, the latest chapter in the battle between Big Pharma and Synergy Pharmaceuticals Virus HSV-1 and HSV-2 titers were reduced significantly by 5CC to the point of being negative, ranging 0.01–0.09 in 72%. These concentrations of the 5CC are nontoxic and reduced plaque formation by 98.2% for HSV-1 and 93.0% for HSV-2. There were high-level markers of the 5CC virucidal activity in viral suspension of HSV-1 and HSV-2. Further tests were performed to evaluate the susceptibility of HSV-1 and HSV-2 to antiherpetic drugs in Vero cells after virus entry. The 50% inhibitory concentration (IC50) of 5CC was 0.0009% for HSV-1 plaque formation and 0.0008% for HSV-2 plaque formation. The activity of the 5CC was tested on RC-37 in vitro using an assay plaque reduction and in vivo against HSV-1 and HSV-2. They were here found to neutralize antiviral reproduction by blocking cell-to-cell infection. The tested 5CC were noted as being functional in the application of eliminating the DNA synthesis of herpes viral interferon (IFN)-induced cellular antiviral response. The treatment consisted of five immunotherapeutic core compounds (5CC), which were hypothesized to be capable of neutralizing human monoclonal antibodies. The present article tests a treatment based on a systemic understanding of how the herpes virus affects cell inhibition and breakdown, and targets different phases of the viral cycle, including the entry stage, reproductive cross mutation, and cell-to-cell infection. Alternatives currently approved for the purposes of clinical administration includes antivirals and a reduced set of nucleoside analogues. There is an immediate need for alternative anti-herpetic treatment options effective for both primary infections and reoccurring reactivations of herpes simplex virus types 1 (HSV-1) and 2 (HSV-2).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |